Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism"

Affiliations

¹ From Department of Cardiology, Lipid Disorders Clinic, Royal Perth Hospital, Perth (G.F.W.); School of Medicine and Pharmacology, University of Western Australia, Perth (G.F.W., D.C.C.); Amgen Inc., Thousand Oaks, CA (R.S., S.M.W.); and TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.S.S.).

Comment

Gerald F Watts et al. Circulation. 2017.

. 2017 Jul 4;136(1):120-121.

doi: 10.1161/CIRCULATIONAHA.117.028790.

¹ From Department of Cardiology, Lipid Disorders Clinic, Royal Perth Hospital, Perth (G.F.W.); School of Medicine and Pharmacology, University of Western Australia, Perth (G.F.W., D.C.C.); Amgen Inc., Thousand Oaks, CA (R.S., S.M.W.); and TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.S.S.).

No abstract available

Comment on

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, Burrows S, R Barrett PH. Watts GF, et al. Circulation. 2017 Jan 24;135(4):338-351. doi: 10.1161/CIRCULATIONAHA.116.025080. Epub 2016 Dec 9. Circulation. 2017. PMID: 27941065 Clinical Trial.
Letter by Koh Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism".
Koh KK. Koh KK. Circulation. 2017 Jul 4;136(1):118-119. doi: 10.1161/CIRCULATIONAHA.117.027744. Circulation. 2017. PMID: 28674099 No abstract available.